Rosumore F 5 Tablet contains Rosuvastatin 5mg and Fenofibrate 160mg, a clinically proven combination used to treat mixed dyslipidemia, high LDL cholesterol, and elevated triglyceride levels.
Rosuvastatin helps reduce LDL (bad cholesterol) and increase HDL (good cholesterol), while Fenofibrate effectively lowers high triglycerides, making the combination suitable for comprehensive lipid management.
Rosumore F belongs to the cardiac, lipid-lowering, and chronic therapy segment, widely prescribed by cardiologists, diabetologists, and general physicians for long-term cardiovascular risk reduction.
For PCD pharma franchise partners, distributors, and exporters, Rosumore F Tablet offers a strong business opportunity due to its continuous demand in cardiac care. It is available for bulk supply, monopoly-based PCD franchise, third-party manufacturing, institutional distribution, and export.